SEARCH

SEARCH BY CITATION

References

  • 1
    Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 41835.
  • 2
    Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immunol Immunopathol 1977; 8: 348.
  • 3
    Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
  • 4
    Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 26772.
  • 5
    Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 14026.
  • 6
    Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 2347.
  • 7
    Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 23842.
  • 8
    Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 316772.
  • 9
    Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 373945.
  • 10
    Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 6003.
  • 11
    Van Der Bom JG, Mauser-Bunschoten EP, Fischer K, Van Den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 4759.
  • 12
    Goudemand J, Rothschild C, Demiguel V, Vinciguerra C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 4651.
  • 13
    Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study. Br J Haematol 2005; 130: 4227.
  • 14
    Fontes E, Carvalho S, Amorim L. Age at the beginning of factor VIII replacement is not a risk factor for inhibitor development in hemophilia A. Haemophilia 2004; 10: 55 (abstract 12 OC 14).
  • 15
    Kreuz W, Auerswald G, Budde U, Lenk H. Inhibitor incidence in previously untreated patients (PUP) with hemophilia A and B – a 10-year follow up of the prospective multicenter study. Blood 2004; 104: 81b (abstract 3983).
  • 16
    Chalmers EA, Williams MD, Richards M, Brown SA, Liesner R, Thomas A, Vidler V, Keeling D, Smith D, Hill FGH, on behalf of the Paediatric Working Party of UKHCDO.. Early FVIII exposure and subsequent inhibitor development in children with severe haemophilia A. J Thromb Haemost 2005; 3 (Suppl.): OR092.
  • 17
    Kenet G, Lubetsky A, Luboshitz J, Bashari D, Ravid B, Martinowitz U. Early single exposure to factor concentrates does not increase the risk for inhibitor development. Haemophilia 2006; 12: 63 (abstract 14 PO 395).
  • 18
    Acharya SS, Dimichele DM. Management of factor VIII inhibitors. Best Pract Res Clin Haematol 2006; 19: 5166.
  • 19
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 4539.
  • 20
    Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz L, Hurst D. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 57483.
  • 21
    Giangrande PL. Safety and efficacy of KOGENATE(R) Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8 (Suppl. 2): 1922.
  • 22
    Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 45767.
  • 23
    Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 242835.
  • 24
    Gruppo R, Chen H, Schroth P, Bray GL. And for the Recombinate PUP Study Group. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): a 7.3 year update. Haemophilia 1998; 4: 228 (abstract 291).
  • 25
    Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 529.
  • 26
    Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 3849.
  • 27
    Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 2005; 11: 2923.
  • 28
    Fredriks AM, Van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000; 47: 31623.
  • 29
    White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
  • 30
    Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost 1993; 69: 87.
  • 31
    Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 34: 187220.
  • 32
    Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, Brooker L, Carcao MD. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 122836.
  • 33
    Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 3015.
  • 34
    Gouw SC, Van Der Bom JG, Van Den Berg HM. . Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 464854.